diaziquone has been researched along with etoposide in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Weiss, RB | 1 |
| Lee, EJ; Reck, K; Schiffer, CA | 1 |
| Carrasco, CH; Charnsangavej, C; Feun, LG; Gianturco, C; Lee, YY; Savaraj, N; Wallace, S; Yung, WK | 1 |
| Allen, SL; Amrein, PC; George, SL; Lee, EJ; Paciucci, PA; Schiffer, CA | 1 |
| Darling, JL; Thomas, DG | 1 |
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Bloomfield, CD; Carroll, AJ; Edwards, CG; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Sterling, LJ; Vardiman, JW | 1 |
2 review(s) available for diaziquone and etoposide
| Article | Year |
|---|---|
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide | 1992 |
New drugs and new delivery techniques.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Bleomycin; Brain Neoplasms; Carboplatin; Carmustine; Cisplatin; Etoposide; Humans; Infusions, Intra-Arterial; Interferons; Nitrosourea Compounds; Organoplatinum Compounds; Rats | 1985 |
2 trial(s) available for diaziquone and etoposide
| Article | Year |
|---|---|
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1998 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
4 other study(ies) available for diaziquone and etoposide
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Blast Crisis; Bone Marrow; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Response of short-term cultures derived from human malignant glioma to aziridinylbenzoquinone, etoposide and doxorubicin: an in vitro phase II trial.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Glioma; Humans; Tumor Cells, Cultured | 2001 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Statistics, Nonparametric; Survival Analysis | 2005 |